Coya Therapeutics, Inc. Common Stock

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing proprietary therapies to enhance the function of regulatory T cells (Tregs). Its pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The lead candidate, COYA 302, is a biologic combination for subcutaneous administration designed to enhance Treg function while depleting T effector function and activated macrophages; it is in Phase 2 trials for amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. Preclinical candidates include COYA 301, COYA 303, COYA 201, COYA 206, and COYA 101. The company collaborates with Dr. Reddy's Laboratories SA on COYA 302 for amyotrophic lateral sclerosis. Founded in 2020, Coya Therapeutics is headquartered in Houston, Texas.